Low-dose modified-release prednisone in axial spondyloarthritis: 3-month efficacy and tolerability

• Published in: Drug design, development and therapy Vol. 10; pp. 3717 - 3724
• Main Authors: Bandinelli, Francesca, Scazzariello, Francesco, Pimenta da Fonseca, Emanuela, Mittermayer Barreto, Santiago, Marcassa, Claudio, Nacci, Francesca, Matucci Cerinic, Marco
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2016; Taylor & Francis Ltd; Dove Medical Press
• Subjects: Adult; Aged; Aged, 80 and over; Ankylosing spondylitis; Anti-Inflammatory Agents - administration & dosage; Anti-Inflammatory Agents - adverse effects; Arthritis; Cohort Studies; Controlled release technology; Cytokines; Dosage and administration; Drug dosages; Drug therapy; Female; Glucocorticoids; Humans; Immune system; Inflammation; Inflammatory bowel disease; Inflammatory diseases; Male; Middle Aged; modified-release prednisone; morning stiffness; Nonsteroidal anti-inflammatory drugs; Original Research; Pain; Pain - drug therapy; Prednisolone; Prednisone; Prednisone - administration & dosage; Prednisone - adverse effects; Retrospective Studies; Rheumatic diseases; Rheumatoid arthritis; Rheumatology; Safety; Short term; Side effects; Signs and symptoms; Spondylarthritis - drug therapy; Spondylarthritis - physiopathology; Spondylitis; Spondylitis, Ankylosing - drug therapy; Spondylitis, Ankylosing - physiopathology; spondyloarthritis; Spondyloarthropathies; Stiffness; Substance abuse treatment; Testing; Tumor necrosis factor-TNF; Italy; modified-release prednisone; spondyloarthritis; glucocorticoids; morning stiffness

Oral glucocorticoids (GCs) have been shown to be effective in reducing the inflammatory symptoms of rheumatoid arthritis, but their use is not supported by evidence in spondyloarthritis (SpA). Modified-release (MR) oral prednisone taken at bedtime has been shown to be more effective than immediate-r...